Immunotech Founder & Chief Scientific Officer Harry Zhabilov Comments on Recent HIV Baby Cure Medicine
12 3월 2013 - 11:45PM
Marketwired
Immunotech Laboratories, Inc. (PINKSHEETS:
IMMB)
Immunotech Company Founder & Chief
Scientific Officer Harry Zhabilov comments on the recent AIDS-HIV
Baby Cure Treatments.
Regarding the recently published articles and Media
announcements of the HIV case with the newborn baby. This
experiment one more time confirms the mechanism of action of
chemotherapy of HIV. This means chemotherapy works only when the
HIV virus is in the blood stream. When the virus reaches all of the
viral reservoirs in the system, it is more difficult for
chemotherapy to extract the virus from the viral reservoirs of the
blood stream. The treatment appears to have been successful because
the virus was already in baby's blood steam the treatment used does
not allow the virus to reach the reservoir like
monocyte-macrophages, Langerhans cells, follicular-dendritic cells,
retinal cells.
By using immunotherapy treatments we are increasing the level of
natural killer cells and CD 8 which are responsible for attacking
the virus in any corner of the system. This is the reason that
chemotherapy has a fast effect under the level of PCR (Polymerase
Chain Reaction) whereas; immunotherapy works slowly but does not
have resistance.
In a recent article presenting the findings said Dr Deborah
Persaud, a virologist at Johns Hopkins University in Baltimore
said, "This is a proof of concept that HIV can be potentially
curable in infants."
Reuters Mar 4, 2013, 09.43AM. IST "Article
Remnant". (Complete article link below)
Because of her risk, Dr Hannah Gay, a pediatric HIV specialist
put the infant on a cocktail of three HIV-fighting drugs --
zidovudine (also known as AZT), lamivudine, and nevirapine -- when
she was just 30 hours old. Two blood tests done within the first 48
hours of the child's life confirmed her infection and she was kept
on the full treatment regimen, Persaud told reporters at the
conference.
In more typical pregnancies, when an HIV-infected mother has
been given drugs to reduce the risk of transmission to her child,
the baby would only have been given a single drug, nevirapine.
Researchers believe use of the more aggressive antiretroviral
treatment when the child was just days old likely resulted in her
cure by keeping the virus from forming hard-to-treat pools of cells
known as viral reservoirs, which lie dormant and out of the reach
of standard medications. These reservoirs rekindle HIV infection in
patients who stop therapy, and they are the reason most
HIV-infected individuals need lifelong treatment to keep the
infection at bay.
RELEVANT ARTICLES & LINKS FOR BABY AIDS-HIV
MEDICINE CURES
http://timesofindia.indiatimes.com//articleshow/18786108.cms?intenttarget=no
http://www.mccormick.northwestern.edu/news/articles/2012/10/david-kelso-HIV-clinical-trial-in-mozambique.html#.UTTtjmHF-PI.email
About Immunotech Laboratories Immunotech
Laboratories is a drug development company committed to the
commercialization of its proprietary proteins for the treatment of
debilitating infectious diseases such as HIV, Cancer, Hepatitis and
Aids. www.immunotechlab.com
Safe Harbor Statement: This news release
contains forward-looking statements that involve risks and
uncertainties associated with financial projections, budgets,
milestone timelines, clinical development, regulatory approvals,
and other risks described by Immunotech Laboratories, Inc. from
time to time in its periodic reports filed with the SEC. IPF is not
approved by the US Food and Drug Administration or by any
comparable regulatory agencies elsewhere in the world. While
Immunotech Laboratories believes that the forward-looking
statements and underlying assumptions contained therein are
reasonable, any of the assumptions could be inaccurate, including,
but not limited to, the ability of Immunotech Laboratories to
establish the efficacy of IPF in the treatment of any disease or
health condition, the development of studies and strategies leading
to commercialization of IPF in the United States, the obtaining of
funding required to carry out the development plan, the completion
of studies and tests on time or at all, and the successful outcome
of such studies or tests. Therefore, there can be no assurance that
the forward-looking statements included in this release will prove
to be accurate. In light of the significant uncertainties inherent
in the forward-looking statements included herein, Immunotech
Laboratories or any other person that the objectives and plans of
Immunotech Laboratories will be achieved should not regard the
forward-looking statements as a representation.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Company Contact: Email Contact Investor Relations: The Nabors
Group 713-875-9200 E-mail: Email Contact
www.facebook.com/Naborsgroup
Immunotech Laborator (CE) (USOTC:IMMB)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Immunotech Laborator (CE) (USOTC:IMMB)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024